Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT01401244 Completed - Healthy Clinical Trials

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

Start date: July 14, 2011
Phase: Phase 1
Study type: Interventional

This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.

NCT ID: NCT01395953 Withdrawn - Clinical trials for Autism Spectrum Disorder (ASD)

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The main objective of this exploratory 8 week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.

NCT ID: NCT01395160 Completed - Bipolar Disorder Clinical Trials

Female Experiences and Brain Activity

FEBA
Start date: July 2011
Phase: N/A
Study type: Observational

The Female Experiences and Brain Activity study will investigate how different groups of people process information in different ways. Using electro-physiological methods it will investigate differences in brain activity between women with ADHD, women with bipolar disorder and those without a psychiatric illness. It will also investigate the relationship between patterns of brain activity, mood and functioning.

NCT ID: NCT01392989 Completed - Anemia Clinical Trials

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Start date: March 2011
Phase: Phase 2
Study type: Interventional

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

NCT ID: NCT01391897 Recruiting - PTSD Clinical Trials

Epigenetics of Posttraumatic Stress Disorder and Somatoform Disorders in the Course of Psychotherapy

TREPS
Start date: January 2011
Phase: N/A
Study type: Observational

This reported observational clinical study aims at identifying epigenetic markers in a sample of patients undergoing high dose inpatient psychotherapy suffering from a variety of psychiatric/psychosomatic diseases such as somatoform disorders, posttraumatic stress disorder (PTSD), depression, anxiety disorders and eating disorders. The exact epigenetic markers that will be traced are yet to define. The investigators believe that 1. Epigenetic patterns found in the group of psychiatric patients show differences from healthy controls 2. Different diagnosis show differences in epigenetic patterns as well 3. Epigenetic patterns correlate to the severity of the psychosocial disorder as measured in interviews or psychometric ratings 4. Epigenetic patterns can change under inpatient high dose psychotherapy 5. Changes correlate to clinical psychometric variables.

NCT ID: NCT01390636 Terminated - Eating Disorder Clinical Trials

Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

REACT5
Start date: July 2011
Phase: N/A
Study type: Observational

The purpose of this study is to use data from the Continuous Glucose Monitor (CGM) to determine the degree of variation in glucose levels of individuals with an eating disorder and type 1 diabetes and only an eating disorder.

NCT ID: NCT01386177 Completed - Clinical trials for Substance-Related Disorders

Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determinate the effect of a pre-treatment with doxazosin, a alpha1-adrenergic receptor blocker, on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The investigators hypothesize that doxazosin will attenuate the cardiovascular and subjective response to MDMA.

NCT ID: NCT01385709 Completed - Clinical trials for Major Depressive Disorder

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

Start date: August 2008
Phase: N/A
Study type: Observational

The aim of this study is to determine whether blood levels of lithium or sertraline are affected by different phases of the menstrual cycle and whether there is an effect on psychiatric symptoms. Subjects are seen for two visits: one visit during the luteal phase and one visit during the follicular phase of the menstrual cycle. On each visit, they will fill out a depression, anxiety and mania rating scale. Also at each visit a 20mL blood sample will be drawn to measure progesterone level and either a lithium or sertraline level, depending on which medication the patient takes. The primary hypothesis in this study is that blood levels of lithium and sertraline will be significantly lower in women during the luteal phase of the menstrual cycle than during the follicular phase. Examination will also be made of whether symptoms will increase in severity during the luteal phase as compared to the follicular phase. The investigators expect a negative linear association between symptom severity and blood level, i.e. expect symptom severity to worsen as blood levels of lithium or sertraline decrease.

NCT ID: NCT01385592 Completed - Parkinson Disease Clinical Trials

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start date: November 2011
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

NCT ID: NCT01384604 Completed - Schizophrenia Clinical Trials

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

BSNIP
Start date: December 2007
Phase:
Study type: Observational

The overall goal of this project is to identify intermediate phenotypes for psychosis across the schizophrenia and bipolar disorders boundary with implications for future genetic studies. Recent studies provide considerable evidence that schizophrenia and psychotic bipolar disorder may share overlapping etiologic determinants. Identifying disease-related genetic effects is a major focus in schizophrenia and bipolar research, with enormous implications for diagnosis and treatment for these two disorders. Efforts have been multifaceted, with the ultimate goal of describing causal paths from specific genetic variants, to changes in neuronal functioning, to altered brain anatomy, to behavioral and functional impairments. Parallel efforts have identified and refined several alternative endophenotypes that are stable, heritable, have (partly) known biological substrates, and are associated with psychosis liability. Although many such endophenotypes have been individually studied in schizophrenia, and to a lesser extent in bipolar disorder, no study has comprehensively assessed a broad panel of these markers in the two disorders with parallel recruitment, and the extent to which they mark independent aspects of psychosis risk, or their overlap in the two disorders. In this research project, we will examine a broad panel of putative endophenotypes in affected individuals and their first degree, biological relatives in order to: 1) characterize the degree of familial phenotypic overlap between schizophrenia and psychotic bipolar disorders; 2) identify patterns of endophenotypes unique to the two disorders; and, 3) contrast the heritability of endophenotypes across the disorders. We will obtain measures of neurophysiology (e.g., eye tracking, P50 gating, PPI, and P300), neurocognition (e.g., attention/vigilance, episodic and working memory), and brain structure (e.g., volumes of gray and white matter in specified brain regions). Blood samples will also be collected and stored for formal DNA linkage analyses using the independent phenotypes identified above. All volunteers will also be given the option to donate dermal biopsies for future research studies. Establishing similarities and differences in the endophenotypic signatures within schizophrenia and bipolar families will provide important insights for future genetic studies, and clarify concepts about common and distinct aspects of pathophysiology, potentially meaningful heterogeneity with disorders, and the clinical boundaries of the two most common psychotic disorders in adult psychiatry. This line of investigation will potentially impact our conceptualization of psychotic disorders, help us make critical strides to identify the pathophysiology of psychosis, and guide development of new specific treatments targeting particular deficits.